— Objective response or stable disease in 100% of renal cell carcinomas The FDA has approved the first therapy for cancers associated with von Hippel-Lindau (VHL) disease. Belzutifan (Welireg) targets hypoxia-inducible factor 2α, which drives growth of malignant and benign tumors in VHL. In the absence of approved systemic therapies, most patients with VHL undergo […]
- Home
- About UROLOGY
- Urology Diseases
- Procedures
- Office Urology procedures
- Dayward procedures
- In-patient procedures 1
- In-patient procedures 2
- Laparoscopic and Open Nephrectomy
- Radical cystectomy / cystoprostatectomy with ileal conduit / neobladder
- Radical prostatectomy with pelvic lymph node dissection for prostate cancers
- Orchidectomy for testicular cancers
- Penile amputation / penectomy with inguinal lymph node dissection for penile cancers
- Penile prosthesis
- Artificial urinary sphincter
- Augmentation Cystoplasty
- Urology Assessment
- Resources
- News Media & Publications